Proficio Capital Partners LLC Takes $22.66 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Proficio Capital Partners LLC purchased a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 64,217 shares of the biotechnology company's stock, valued at approximately $22,658,000. Proficio Capital Partners LLC owned 0.14% of United Therapeutics at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC raised its holdings in United Therapeutics by 4.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company's stock valued at $391,459,000 after acquiring an additional 45,566 shares in the last quarter. FMR LLC raised its holdings in shares of United Therapeutics by 41.1% during the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company's stock worth $386,168,000 after buying an additional 314,004 shares in the last quarter. Pacer Advisors Inc. raised its holdings in shares of United Therapeutics by 5.5% during the 4th quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company's stock worth $210,869,000 after buying an additional 30,931 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of United Therapeutics by 12.3% during the 3rd quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company's stock worth $164,978,000 after buying an additional 50,409 shares in the last quarter. Finally, Assetmark Inc. raised its holdings in shares of United Therapeutics by 2.2% during the 4th quarter. Assetmark Inc. now owns 429,160 shares of the biotechnology company's stock worth $151,425,000 after buying an additional 9,203 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Remove Ads

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Nilda Mesa sold 255 shares of the firm's stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the sale, the director now owns 5,528 shares of the company's stock, valued at approximately $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Louis W. Sullivan sold 26,209 shares of the firm's stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the sale, the director now directly owns 5,051 shares of the company's stock, valued at $1,885,134.22. This trade represents a 83.84 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 116,464 shares of company stock valued at $42,396,244. Company insiders own 11.90% of the company's stock.

United Therapeutics Stock Down 2.7 %

Shares of NASDAQ UTHR traded down $8.82 during trading on Tuesday, reaching $314.12. The company had a trading volume of 417,946 shares, compared to its average volume of 443,820. The company's fifty day moving average price is $349.12 and its 200-day moving average price is $358.27. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82. The stock has a market cap of $14.11 billion, a P/E ratio of 13.80, a PEG ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. During the same quarter in the prior year, the company earned $4.36 EPS. As a group, equities analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. StockNews.com cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 27th. HC Wainwright reaffirmed a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. Finally, UBS Group upped their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.